Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
The Bamboo Works

Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay

Key Takeaways:

  • The company logged a revenue fall of 55% in the first half of the year and posted a loss of $131 million
  • Phase 3 clinical trials for its Covid-19 oral drug wrapped up in May but the company has still not yet filed an application to market the product  
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.